306934-84-9

Basic information

• Product Name: TERT-BUTYL 4-(4-METHOXYANILINO)TETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE
• Synonyms: TERT-BUTYL 4-(4-METHOXYANILINO)TETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE;4-(4-METHOXY-PHENYLAMINO)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1-BOC-4-(4-METHOXYPHENYLAMINO) PIPERIDINE;4-[(4-Methoxyphenyl)amino]piperidine, N1-BOC protected;tert-Butyl 4-(4-methoxyanilino)tetrahydropyridine-1-carboxylate;N-BOC-4-(4-Methoxyanilino)piperidine
• CAS NO: 306934-84-9
• Molecular Formula: C₁₇H₂₆N₂O₃
• Molecular Weight: 306.4
• Mol File: 306934-84-9.mol

Chemical Properties

• Melting Point: 82 °C
• Boiling Point: 435.9 °C at 760 mmHg
• Flash Point: 217.4 °C
• Appearance: /
• Density: 1.119 g/cm³
• Vapor Pressure: 8.46E-08mmHg at 25°C
• Refractive Index: 1.551
• CAS DataBase Reference: TERT-BUTYL 4-(4-METHOXYANILINO)TETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 4-(4-METHOXYANILINO)TETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE(306934-84-9)
• EPA Substance Registry System: TERT-BUTYL 4-(4-METHOXYANILINO)TETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE(306934-84-9)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 306934-84-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
TERT-BUTYL 4-(4-METHOXYANILINO)TETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE is used as a chemical intermediate for the synthesis of various drugs and pharmaceutical compounds. Its unique structure and properties make it a valuable component in the development of new medications and therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical industry, TERT-BUTYL 4-(4-METHOXYANILINO)TETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE is utilized as a precursor in the production of various agrochemicals, including pesticides and herbicides. Its role in these applications contributes to the development of more effective and targeted agricultural products.
Used in Organic Compounds Synthesis:
TERT-BUTYL 4-(4-METHOXYANILINO)TETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE is also employed as a key intermediate in the synthesis of a wide range of organic compounds. Its versatile chemical properties allow it to be incorporated into various molecular structures, enabling the creation of new and innovative materials with diverse applications.

InChI:InChI=1/C17H26N2O3/c1-17(2,3)22-16(20)19-11-9-14(10-12-19)18-13-5-7-15(21-4)8-6-13/h5-8,14,18H,9-12H2,1-4H3

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 104-94-9 4-methoxy-aniline 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 459-60-9 1-fluoro-4-methoxybenzene 

Downstream Products

• 319427-82-2 4-[(4-methoxy-phenyl)-propionyl-amino]-piperidine-1-carboxylic acid tert-butyl ester 
• 319427-83-3 4-[methanesulfonyl-(4-methoxy-phenyl)-amino]-piperidine-1-carboxylic acid tert-butyl ester 
• 319427-84-4 4-[(4-methoxy-phenyl)-(toluene-4-sulfonyl)-amino]-piperidine-1-carboxylic acid tert-butyl ester 
• 319427-86-6 4-[3-(3,5-dimethoxy-benzyl)-1-(4-methoxy-phenyl)-ureido]-piperidine-1-carboxylic acid tert-butyl ester 
• 319427-87-7 4-[3-isopropyl-1-(4-methoxy-phenyl)-ureido]-piperidine-1-carboxylic acid tert-butyl ester 
• 501673-52-5 1-(tert-Butoxycarbonyl)-4-[N-(4-methoxyphenyl)-N-[3-(3,4,5-trimethoxyphenyl)benzyl]amino]piperidine 
• 874986-22-8 tert-butyl 4-[cyclohexyl(4-methoxy-phenyl)amino]piperidine-1-carboxylate 
• 501673-48-9 1-(tert-butoxycarbonyl)-4-[N-(4-methoxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)-pyridin-4-yl]methyl]amino]piperidine 
• 501670-54-8 1-(tert-butoxycarbonyl)-4-[N-(4-methoxyphenyl)-N-[3-(3,4,5-trimethoxyphenyl)-benzoyl]amino]piperidine 
• 501674-52-8 1-(tert-Butoxycarbonyl)-4-[N-[2-(4-ethoxyphenyl)pyridin-4-yl]methyl-N-(4-methoxyphenyl)amino]piperidine 
• 1350809-14-1 C₁₉H₂₄N₂O 
• 1350809-25-4 C₂₀H₂₃N₃O 
• 856932-91-7 C₂₄H₃₂N₂O₃ 
• 1350809-10-7 C₂₅H₃₁N₃O₃ 

Relevant articles and documents

Nucleophilic Aromatic Substitution of Unactivated Aryl Fluorides with Primary Aliphatic Amines by Organic Photoredox Catalysis

In this work, a mild and transition-metal-free approach for the nucleophilic aromatic substitution (SNAr) of unactivated fluoroarenes with primary aliphatic amines to form aromatic amines is reported. This reaction is facilitated by the formati

Amines based on electron-rich fluoroaromatic hydrocarbons, and preparation method of amines

The invention provides amines based on electron-rich fluoroaromatic hydrocarbons, and a preparation method of the amines. The structure of the amines is as shown in a formula I. The invention also provides the preparation method of the amines based on the

Titanium-mediated amination of Grignard reagents using primary and secondary amines

Make it, then break it: N-chlorosuccinimide (NCS) was employed as the oxidant in the synthesis of aniline derivatives using the title transformation (see scheme). Functionalization was well tolerated on both the amine and Grignard reagent. An androgen receptor agonist and several analogues were synthesized to demonstrate the utility of this method.

Design and synthesis of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication

A series of CCR5 antagonists were optimized for potent inhibition of R5 HIV-1 replication in peripheral blood mononuclear cells. Compounds that met acceptable ADME criteria, selectivity, human plasma protein binding, potency shift in the presence of α-glycoprotein were evaluated in rat and dog pharmacokinetics.

AMINOPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF

The present invention relates to compounds of formula (I) as defined herein that are melanocortin receptor agonists, to the preparation thereof and to the therapeutic use thereof in the treatment and in the prevention of obesity, diabetes and sexual dysfunctions that can affect both sexes, in the treatment of cardiovascular diseases, and also in anti-inflammatory uses or in the treatment of alcohol dependency.

ERYTHROPOIETIN PRODUCTION ACCELERATOR

The present invention relates to a preventive or therapeutic agent for pathological conditions caused by reduced production of erythropoietin, or for anemia, or for chronic anemia, renal anemia, aplastic anemia, or pure red cell aplasia, the agent comprising, as an active ingredient, a cyclic amine compound represented by the following formula (1): wherein, ???R1, R2 and R3 each independently represent a hydrogen atom, a halogen atom, or hydroxy, alkyl, halogen-substituted alkyl, alkoxy, alkylthio, carboxyl, alkoxycarbonyl or alkanoyl group; ???W1 and W2 each independently represent N or CH; ???X represents O, NR4, CONR4 or NR4CO; ???R4 each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl group; and ???l, m and n each represents a number of 0 or 1, or a salt thereof or a solvate thereof.

Cyclic amine compounds and pharmaceutical composition containing the same

A cyclic amine compound by the following general formula (1): wherein, R1, R2and R3each independently represent a hydrogen atom or an alkoxy group W1and W2each independently represent N or CH; X represents O, NR4, CONR4or NR4CO; R4represents a hydrogen atom, or an alkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl group; and l, m and n each represents a number of 0 or 1, a salt thereof and a hydrate thereof are provided. These compounds have inhibitory effects on both cell adhesion and cell infiltration and are useful as anti-asthmatic agents, anti-allergic agents, anti-rheumatic agents, anti-arteriosclerotic agents, anti-inflammatory agents, anti-Sjogren's syndrome agents or the like.

Multistep solution-phase parallel synthesis of spiperone analogues

A flexible, multistep parallel synthesis of spiperone analogues is described. A library of 4-substituted piperidines, assembled utilizing reductive amination and acylation protocols, was alkylated either homogeneously or heterogeneously, exploiting a product release only concept, to afford an oxa-series of spiperone analogues. Screening of the products at 5-HT2 and D2 receptors revealed 5-HT(2A) antagonists with improved selectivity compared to spiperone and AMI-193. (C) 2000 Published by Elsevier Science Ltd.